Lipitor In The Prevention Of Stroke, For Patients Who Have Had A Previous Stroke

Pfizer4,732 enrolled

Overview

To determine whether Lipitor reduces stroke, compared to placebo in patients who have had a previous stroke or transient ischemic attack.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

4,732

Conditions

Cardiovascular Disease

Interventions

atorvastatinDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Previous stroke or TIA Exclusion Criteria: * coronary heart disease

Locations (130)

Outcomes

Primary Outcomes

Time to occurrence of fatal or non-fatal stroke

Secondary Outcomes

Time to occurrence of an acute coronary event, consisting of cardiac death, nonfatal myocardial infarction, resuscitated cardiac arrest or unstable angina.

Time to occurrence of a cerebrovascular event, defined as fatal or nonfatal stroke or TIA.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Pfizer Investigational Site

East Gosford, New South Wales, Australia

Pfizer Investigational Site

Randwick, Sydney, New South Wales, Australia

Pfizer Investigational Site

Footscray, Victoria, Australia

Pfizer Investigational Site

Heidelberg Heights, Victoria, Australia

Pfizer Investigational Site

Parkville, Victoria, Australia

Pfizer Investigational Site

Prahran, Victoria, Australia

Pfizer Investigational Site

Perth, Western Australia, Australia

Pfizer Investigational Site

Graz, Austria

Pfizer Investigational Site

Innsbruck, Austria

Pfizer Investigational Site

Vienna, Austria

...and 120 more locations